Emcure Q1 PAT Jumps 41% YoY

  Published 8 months ago

Emcure Pharma posted 41% YoY PAT growth to ₹215 crore in Q1, with strong gains across domestic and global markets.

  • Revenue rose 15.7% YoY to ₹2,101 crore, driven by domestic therapy growth and robust global performance.
  • International sales grew 22%, led by 42% RoW growth and strong launches in Canada (16.4%) and Europe (12.8%).
  • EBITDA grew 20.1% with 19.2% margins; strong product pipeline and Sanofi tie-up to drive future growth.

You might like these

Germany Seeks EU Funding for AI Data Center

South Indian Bank Growth Q2 2025: Key Metrics

Kalpataru Wins Global T&D & B&F Orders

India Services PMI Hits 11-Month High

LTTS Secures $50M Sustainability Deal with Energy Major

Equitas Bank Capital Raise & Overview

India's $300B Bioeconomy Mission 2030

News that matters the most ⚡